ClinicalTrials.gg

Program

CD47 Antagonist AUR103 Calcium

Its studies are mostly in Neoplasms · Stomach Neoplasms, led by Dr. Reddy's Laboratories.

Furthest: phase 2, since Jun 4, 20252 company-led studies, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Reddy's Laboratories21 open or runningphase 2since Jun 4, 2025Jun 4, 2025Dec 30, 2028phase 2 · NCT07640737

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2025First study: phase 2 study in HER 2 Positive Gastric CancerFirst studyNCT07040059 · 2 enrolled · India
  2. Jun 3, 2026Phase 2 study in NeoplasmsNCT07640737 · 30 planned · United States

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in NeoplasmsNCT07640737

TargetBeta

CD47 →read by rule
“The calcium salt form of AUR103, an orally bioavailable, small molecule antagonist of the human cell surface antigen CD47, ”NCIt, by rule

Other programs on CD47

ProgramCompanyFurthest phaseStudies
ligufalimabruleAkesophase 311
evorpaceptrulealx-oncology-incphase 39
Anti-PD-1/CD47 Fusion Protein HX009rulehangzhou-hanx-biopharmaceuticals-ltdphase 25
1200mg of tqb2928 injectionSino Biopharmaceuticalphase 12

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07640737Neoplasms · United States2Not yet recruitingDec 30, 202830
NCT07040059HER 2 Positive Gastric Cancer · India2TerminatedDec 29, 20252

How it is read

Names in the registry

  • “AUR103 Calcium”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.